Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

SGLT2 inhibitors: Clinical benefits by restoration of normal diurnal metabolism?

Publikation: Bidrag til tidsskriftReviewForskningpeer review

DOI

  1. Risk factors for hyperglycemia in pregnancy in the DALI study differ by period of pregnancy and OGTT time point

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Safety and convenience of once-weekly somapacitan in adult GH deficiency: a 26-week randomized, controlled trial

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Genetic influence on the associations between IGF-I and glucose metabolism in a cohort of elderly twins

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Targeting either GH or IGF-I during somatostatin analogue treatment in patients with acromegaly: a randomized multicentre study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Prediction of carotid intima-media thickness and its relation to cardiovascular events in persons with type 2 diabetes

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Dyslipidemia at diagnosis of childhood acute lymphoblastic leukemia

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Lactation Duration and Long-term Risk for Incident Type 2 Diabetes in Women With a History of Gestational Diabetes Mellitus

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Russell L. Esterline
  • Allan Vaag
  • Jan Oscarsson
  • Jiten Vora
Vis graf over relationer

Type 2 diabetes (T2D) is associated with inhibition of autophagic and lysosomal housekeeping processes that detrimentally affect key organ functioning; a process likely to be exacerbated by conventional insulin-driven anabolic therapies. We propose that the cardio-renal benefits demonstrated with sodium-glucose cotransporter-2 inhibitor (SGLT2i) treatment in T2D partly may be explained by their ability to drive consistent, overnight periods of increased catabolism brought about by constant glucosuria. Key steps driving this catabolic mechanism include: a raised glucagon/insulin ratio initially depleting glycogen in the liver and ultimately activating gluconeogenesis utilizing circulating amino acids (AAs); a general fuel switch from glucose to free fatty acids (accompanied by a change in mitochondrial morphology from a fission to a sustained fusion state driven by a decrease in AA levels); a decrease in circulating AAs and insulin driving inhibition of mammalian target of rapamycin complex 1 (mTORC1), which enhances autophagy/lysosomal degradation of dysfunctional organelles, eventually causing a change in mitochondrial morphology from a fission to a sustained fusion state. Resumption of eating in the morning restores anabolic biogenesis of new and fully functional organelles and proteins. Restoration of diurnal metabolic rhythms and flexibility by SGLT2is may have therapeutic implications beyond those already demonstrated for the cardio-renal axis and may therefore affect other non-diabetes disease states.

OriginalsprogEngelsk
TidsskriftEuropean Journal of Endocrinology
Vol/bind178
Udgave nummer4
Sider (fra-til)R113-R125
ISSN0804-4643
DOI
StatusUdgivet - 1 apr. 2018

ID: 59277576